Lu AA 47070

Discontinued Product

4783 has been discontinued.

View all Adenosine A<sub>2A</sub> Receptors products.
说明: Prodrug of a potent and selective adenosine A2A receptor antagonist
化学名: 4-[(3,3-Dimethyl-1-oxobutyl)amino]-3,5-difluoro-N-[3-[(phosphonooxy)methyl]-2(3H)-thiazolylidene]benzamide
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for Lu AA 47070

Prodrug of a potent and selective adenosine A2A receptor antagonist (Ki values are 5.9, 260, 410 and <10,000 nM for A2A, A2B, A1 and A3 receptors respectively. Reverses parkinsonian motor impairment and motivational effects produced by dopamine D2 receptor blockade in rats. Orally bioavailable.

技术数据 for Lu AA 47070

分子量 463.39
公式 C17H20F2N3O6PS
储存 Store at +4°C
纯度 ≥98% (HPLC)
CAS Number 913842-25-8
PubChem ID 11947802
InChI Key MSWIQSFUBYCFJE-UHFFFAOYSA-N
Smiles FC1=C(NC(CC(C)(C)C)=O)C(F)=CC(C(/N=C2\SC=CN2COP(O)(O)=O)=O)=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Adenosine A2A Receptor Antagonists

关键词: Lu AA 47070, Lu AA 47070 supplier, LuAA47070, prodrug, potent, selective, adenosine, A2A, receptors, antagonists, parkinson's, disease, antiparkinson, parkinsonian, orally, bioavailable, Adenosine, Receptors, 4783, Tocris Bioscience

篇 Lu AA 47070 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 Lu AA 47070 的引用文献。

Lu AA 47070 的评论

目前没有该产品的评论。 Be the first to review Lu AA 47070 and earn rewards!

Have you used Lu AA 47070?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.